TWI862645B - 腺苷衍生物及包含其之醫藥組合物 - Google Patents

腺苷衍生物及包含其之醫藥組合物 Download PDF

Info

Publication number
TWI862645B
TWI862645B TW109125342A TW109125342A TWI862645B TW I862645 B TWI862645 B TW I862645B TW 109125342 A TW109125342 A TW 109125342A TW 109125342 A TW109125342 A TW 109125342A TW I862645 B TWI862645 B TW I862645B
Authority
TW
Taiwan
Prior art keywords
methyl
ethynyl
fluoro
purin
amino
Prior art date
Application number
TW109125342A
Other languages
English (en)
Chinese (zh)
Other versions
TW202118496A (zh
Inventor
徐連紅
Original Assignee
美商布里生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商布里生物科學股份有限公司 filed Critical 美商布里生物科學股份有限公司
Publication of TW202118496A publication Critical patent/TW202118496A/zh
Application granted granted Critical
Publication of TWI862645B publication Critical patent/TWI862645B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109125342A 2019-07-27 2020-07-27 腺苷衍生物及包含其之醫藥組合物 TWI862645B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962879414P 2019-07-27 2019-07-27
US62/879,414 2019-07-27

Publications (2)

Publication Number Publication Date
TW202118496A TW202118496A (zh) 2021-05-16
TWI862645B true TWI862645B (zh) 2024-11-21

Family

ID=74229552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109125342A TWI862645B (zh) 2019-07-27 2020-07-27 腺苷衍生物及包含其之醫藥組合物

Country Status (12)

Country Link
US (2) US12370208B2 (https=)
EP (1) EP4003369A4 (https=)
JP (1) JP7700096B2 (https=)
KR (1) KR20220068987A (https=)
CN (1) CN114502175B (https=)
AU (1) AU2020320876B2 (https=)
BR (1) BR112022000965A2 (https=)
CA (1) CA3146679A1 (https=)
IL (1) IL289925B2 (https=)
MX (1) MX2022000563A (https=)
TW (1) TWI862645B (https=)
WO (1) WO2021021717A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
IL307967A (en) * 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CR20250310A (es) * 2023-01-30 2025-08-25 Merck Sharp & Dohme Llc Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'
CN121419986A (zh) * 2023-06-27 2026-01-27 吉利德科学公司 用于制备抗病毒前药的方法和中间体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526237A (en) * 2003-09-05 2005-08-16 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
US8039614B2 (en) * 2004-03-24 2011-10-18 Yamasa Corporation 4' -C-substituted-2-haloadenosine derivative
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
WO2007022073A2 (en) * 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
US20160199396A1 (en) 2013-08-29 2016-07-14 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20180030080A1 (en) 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
US10266558B2 (en) 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
DK3590924T3 (da) 2017-02-28 2022-01-03 Kangpu Biopharmaceuticals Inc Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
US10676252B2 (en) * 2017-12-21 2020-06-09 Helen Of Troy Limited Container with sealable lid
DE102018200487A1 (de) * 2018-01-12 2019-07-18 Knorr-Bremse Systeme für Schienenfahrzeuge GmbH Vorrichtung und Verfahren zur Realisierung kontrollierter Reaktionen bei einer Systemstörung
CN109053803A (zh) * 2018-07-04 2018-12-21 米文君 一类新的化合物及其用途
AU2019317810A1 (en) * 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
JP2021536444A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
CN113811360A (zh) * 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2021038509A1 (en) * 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
KR20220066303A (ko) * 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
EP4171526A4 (en) 2020-06-27 2024-11-27 Laurus Labs Limited ORAL FILM FROM HIV MEDICATIONS
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
WO2023196832A2 (en) 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526237A (en) * 2003-09-05 2005-08-16 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
US8039614B2 (en) * 2004-03-24 2011-10-18 Yamasa Corporation 4' -C-substituted-2-haloadenosine derivative
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof

Also Published As

Publication number Publication date
JP7700096B2 (ja) 2025-06-30
BR112022000965A2 (pt) 2022-06-14
US12370208B2 (en) 2025-07-29
JP2022541667A (ja) 2022-09-26
MX2022000563A (es) 2022-06-17
KR20220068987A (ko) 2022-05-26
US20220288098A1 (en) 2022-09-15
CN114502175B (zh) 2025-02-25
US20230226093A1 (en) 2023-07-20
CA3146679A1 (en) 2021-02-04
AU2020320876B2 (en) 2025-09-25
EP4003369A1 (en) 2022-06-01
IL289925A (en) 2022-03-01
IL289925B2 (en) 2026-03-01
TW202118496A (zh) 2021-05-16
EP4003369A4 (en) 2023-10-18
WO2021021717A1 (en) 2021-02-04
AU2020320876A1 (en) 2022-02-03
CN114502175A (zh) 2022-05-13
IL289925B1 (en) 2025-11-01

Similar Documents

Publication Publication Date Title
TWI862645B (zh) 腺苷衍生物及包含其之醫藥組合物
US9714243B2 (en) 4-pyridinonetriazine derivatives as HIV integrase inhibitors
RU2720811C2 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
CN116801884B (zh) 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法
US20190185508A1 (en) Deuterated nucleoside reverse transcriptase inhibitors
JP7843289B2 (ja) アデノシン誘導体及びそれを含む医薬組成物
RU2824528C2 (ru) Аденозиновое производное и фармацевтическая композиция, содержащая его
HK40074714A (en) Adenosine derivative and pharmaceutical composition comprising the same
HK40074714B (zh) 腺苷衍生物和包含其的药物组合物
EA050361B1 (ru) Комбинированная терапия вич с производными аденозина и ингибиторами капсидов